One of the world’s biggest trials of COVID-19 therapies released its long-awaited interim results yesterday—and they’re a letdown. None of the four treatments in the Solidarity trial, which enrolled more than 11,000 patients in 400 hospitals around the globe, increased survival—not even the much-touted antiviral drug remdesivir.  The results, announcedContinue Reading

Healthy young people might not get the coronavirus vaccine until 2022 as public health officials focus on immunizing the elderly and other vulnerable groups first, top officials from the World Health Organization said Wednesday. Researchers have been warning that production constraints and hoarding could limit SARS-CoV-2 vaccine supplies. This warningContinue Reading

While early research on asymptomatic transmission has shown that some asymptomatic individuals will test positive two to three days before developing symptoms, we would definitely not expect a positive diagnostic test for COVID-19 one day after exposure. The diagnostic test, known as a “PCR test,” works by detecting genetic materialContinue Reading

An organization aims to compare “apples to apples” and analyze data from all of the experimental drugs that reach clinical trials to determine which COVID-19 vaccine candidates have the best chances of beating the virus.The Coalition for Epidemic Preparedness Innovations (CEPI), which is funding in part some of the vaccinesContinue Reading

CNBC interviewed five participants — three in Moderna’s study and two in Pfizer’s late-stage trials — about their symptoms after getting vaccinated. While the symptoms were uncomfortable, and at times intense, they often went away after a day, sometimes sooner, according to three participants in the Moderna trial and one in Pfizer’sContinue Reading